The US Food and Drug Administration (FDA) has granted 510K clearance for Royal Biologics’ MAXX-BMC bone marrow aspirate concentration system.

The device has been designed for use at point of care setting to provide optimal samples of concentrated bone marrow aspirate (BMA) from a patient to users.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Developed using the company’s patented Lead Screw technology, the MAXX- BMC system allows users to prepare an autologous concentrated BMA product with enhanced stem cell concentration.

The technology allows users to prepare a customised sample at point of care setting for orthopaedic and sports medicine surgical procedures’ use.

Concentrated BMA is a biologic concentrate, which is derived from the patients’ own bone marrow and contains many hematopoietic stem cells and mesenchymal stem cells.

See Also:

They have shown to be critical during biological processes like tissue regeneration and bone formation.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Royal Biologics said in a statement: “Maxx-BMC’s patented Lead Screw technology provides users the most flexible and versatile bone marrow aspirate concentration system on the market.

“The addition of MAXX-BMC to our growing Enhanced Autologous Healing portfolio now puts Royal Biologics in the position as a go-to provider for autologous, advanced cellular therapies.

“Our goal is to harness the power and ability of the patients own cells to help treat a wide variety of specialties at a fraction of the cost of other expensive bone graft substitutes and allogenic options on the market.”

The new bone marrow aspirate concentration system is marked as the latest addition to the company’s portfolio of Advanced Cellular Technologies & Enhanced Autologous Healing solutions.

The company noted that the Lead Screw technology will enable clinicians to accurately locate the areas of ‘Buffy Coat’ fraction of bone marrow aspirate, in seconds after concentration.

Furthermore, the system has the capability to provide up to two concentration cycles within eight minutes.